These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25639804)

  • 1. Pulmonary hypertension management in neonates.
    Pandya KA; Puligandla PS
    Semin Pediatr Surg; 2015 Feb; 24(1):12-6. PubMed ID: 25639804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.
    Oishi P; Datar SA; Fineman JR
    Expert Opin Pharmacother; 2011 Aug; 12(12):1845-64. PubMed ID: 21609302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure.
    Yin J; Kukucka M; Hoffmann J; Sterner-Kock A; Burhenne J; Haefeli WE; Kuppe H; Kuebler WM
    Circ Heart Fail; 2011 Mar; 4(2):198-206. PubMed ID: 21216837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary hypertension in infancy and childhood.
    Mathew R; Gewitz MH
    Heart Dis; 2000; 2(5):362-8. PubMed ID: 11728283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should patients with pulmonary hypertension and increased pulmonary resistance be treated with vasodilators?
    Rich S
    Cardiovasc Clin; 1990; 21(1):265-74; discussion 275-6. PubMed ID: 2199052
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of pharmacologic interventions--treating endothelial dysfunction and group 2 pulmonary hypertension.
    Guazzi M; Gomberg-Maitland M; Naeije R
    Prog Cardiovasc Dis; 2015; 57(5):473-9. PubMed ID: 25446553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
    Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
    J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pulmonary hypertension of the newborn - mechanisms of failed circulatory adaptation after birth, clinical presentation and diagnosis].
    Vakrilova L
    Akush Ginekol (Sofiia); 2014; 53(3):34-40. PubMed ID: 25509644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds.
    Hagan G; Pepke-Zaba J
    Expert Rev Respir Med; 2011 Apr; 5(2):163-71. PubMed ID: 21510727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of structural remodeling in chronic pulmonary hypertension.
    Durmowicz AG; Stenmark KR
    Pediatr Rev; 1999 Nov; 20(11):e91-e102. PubMed ID: 10551895
    [No Abstract]   [Full Text] [Related]  

  • 11. Vasoproliferation and antiproliferative treatment options in pulmonary arterial hypertension.
    Blaukovitsch M; Zabel P; Hauber HP
    Recent Pat Cardiovasc Drug Discov; 2009 Jun; 4(2):142-9. PubMed ID: 19519556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Primary pulmonary hypertension and its management].
    Crespo Martínez C; Morales León V; Alonso Ramos H; Alonso Ortiz B; Molero Gómez R
    Farm Hosp; 2004; 28(1):48-55. PubMed ID: 15012178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension.
    Klinger JR; Abman SH; Gladwin MT
    Am J Respir Crit Care Med; 2013 Sep; 188(6):639-46. PubMed ID: 23822809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the endothelium in pulmonary arterial hypertension.
    Haworth SG
    Vascul Pharmacol; 2006 Nov; 45(5):317-25. PubMed ID: 17005453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current therapeutics and practical management strategies for pulmonary arterial hypertension.
    Agarwal R; Gomberg-Maitland M
    Am Heart J; 2011 Aug; 162(2):201-13. PubMed ID: 21835279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the serotonin pathway as a therapeutic target for pulmonary hypertension.
    Gray EA; Tsuchimochi H; Pearson JT; Sonobe T; Fujii Y; Yoshimoto M; Umetani K; Shirai M; Schwenke DO
    J Synchrotron Radiat; 2013 Sep; 20(Pt 5):756-64. PubMed ID: 23955040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents.
    Rubin LJ
    Am J Respir Crit Care Med; 2002 Nov; 166(10):1308-9. PubMed ID: 12421739
    [No Abstract]   [Full Text] [Related]  

  • 18. The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury.
    Lahm T; Crisostomo PR; Markel TA; Wang M; Lillemoe KD; Meldrum DR
    Shock; 2007 Jul; 28(1):4-14. PubMed ID: 17510598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology and pathobiology of pulmonary hypertension.
    Guignabert C; Dorfmuller P
    Semin Respir Crit Care Med; 2013 Oct; 34(5):551-9. PubMed ID: 24037624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic pulmonary hypertension--causes, effects, therapy].
    Hombach V; Wieshammer S; Hetzel M
    Klin Anasthesiol Intensivther; 1995; 47():221-40. PubMed ID: 7715176
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.